Drug Experts Concerned About Increased Chinese-Drug Exports To U.S., Europe (China)
This article was originally published in PharmAsia News
Executive Summary
Pharmaceutical companies in China have doubled their exports to the United States in the past five years, and some industry experts are raising national-security concerns. They note that the ingredients for anthrax vaccines no longer exist in the West, leaving the area to rely on China and India to produce the drugs after Western supplies are exhausted. There also are concerns about the safety of Chinese factories and the long-term stability of trade between China, and U.S. European industry experts voice similar national-security concerns. (Click here for more
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.